Next Article in Journal
A New Look at the Structures of Old Sepsis Actors by Exploratory Data Analysis Tools
Next Article in Special Issue
Antifungal, Antitumoral and Antioxidant Potential of the Danube Delta Nymphaea alba Extracts
Previous Article in Journal
Potential Persistent Borrelia Infection and Response to Antibiotic Therapy; a Clinical Case Study and Review of Recent Literature
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 8
Issue 4
10.3390/antibiotics8040224
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Investigations into the Structure/Antibacterial Activity Relationships of Cyclam and Cyclen Derivatives

by
Luis G. Alves
1,*,
João F. Portel
2,3,
Sílvia A. Sousa
2,
Olga Ferreira
4,5,
Stephanie Almada
3,4,
Elisabete R. Silva
4,5,
Ana M. Martins
3 and
Jorge H. Leitão
2,*
1
Centro de Química Estrutural, Associação do Instituto Superior Técnico para a Investigação e Desenvolvimento, 1049-003 Lisboa, Portugal
2
IBB-Instituto de Bioengenharia e Biociências, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal
3
Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal
4
BioISI—Biosystems & Integrative Sciences Institute, Faculdade de Ciências da Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal
5
CERENA—Centro de Recursos Naturais e Ambiente, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal
*
Authors to whom correspondence should be addressed.
Antibiotics 2019, 8(4), 224; https://doi.org/10.3390/antibiotics8040224
Submission received: 22 October 2019 / Revised: 8 November 2019 / Accepted: 12 November 2019 / Published: 14 November 2019
(This article belongs to the Special Issue New Insights into Antibacterial Compounds: From Synthesis and Discovery to Molecular Mechanisms of Action)
Browse Figures
Review Reports Versions Notes

Abstract

:
A series of cyclam- and cyclen-derived salts are described in the present work; they were designed specifically to gain insights into their structure and antibacterial activity towards Staphylococcus aureus and Escherichia coli, used respectively, as Gram-positive and Gram-negative model organisms. The newly synthesized compounds are monosubstituted and trans-disubstituted tetraazamacrocycles that display benzyl, methylbenzyl, trifluoromethylbenzyl, or trifluoroethylbenzyl substituents appended on the nitrogen atoms of the macrocyclic ring. The results obtained show that the chemical nature, polarity, and substitution patterns of the benzyl groups, as well as the number of pendant arms, are critical parameters for the antibacterial activity of the cyclam-based salts. The most active compounds against both bacterial strains were the trans-disubstituted cyclam salts displaying CF3 groups in the para-position of the aromatic rings of the macrocyclic pendant arms. The analogous cyclen species presents a lower activity, revealing that the size of the macrocyclic backbone is an important requirement for the antibacterial activity of the tetraazamacrocycles. The nature of the anionic counterparts present on the salts was found to play a minor role in the antibacterial activity.

Graphical Abstract

1. Introduction

The discovery and use of antibiotics has revolutionized modern medicine, reaching its golden age between the 1940s and the mid-1960s with the discovery of β-lactams, aminoglycosides, tetracyclines, glycopeptides, macrolides, chloramphenicols, ansamycins, and streptogramins [1], which are still currently in clinical use. In the 1980s and 1990s, many pharmaceutical companies abandoned antibiotics research and development, mainly because of the huge investment required and regulatory barriers [2]. Together with the shortage of investment in novel antibiotics [3], a steady worldwide increase in microbial resistance to antibiotics has been reported. Presently, resistance to multiple antibiotics is estimated to cause a total of 700,000 deaths per year worldwide. This impressive death toll is estimated to reach 10 million by 2050, with a huge negative social and economic global impact. Furthermore, infections caused by multiresistant organisms is presently associated with extended hospitalization periods causing a severe burden to healthcare systems worldwide [4]. A particular group of bacterial pathogens encompassing Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanni, Pseudomonas aeruginosa, and Enterobacter species (the ESKAPE group) has been highlighted as being of particular concern due to their increasing prevalence in hospital infections and resistance to multiple antibiotics [5]. The shortage of clinically effective antimicrobials to treat multiresistant bacteria is driving the search for novel antibiotics with novel modes of action or with interacting targets distinct from those already known for compounds which are clinically in use [6].
Cyclam and cyclen are tetraazamacrocycles capable of strongly binding to a wide range of metal ions with numerous applications in medicine [7,8,9,10]. Remarkably, a bis-cyclam derivative was found to be a highly potent and selective inhibitor of HIV; it functions by interacting with receptor number 4 for cytokines that display a Cys–X–Cys sequence (CXCR4), which is used by HIV to enter T-cells [7]. The virus’ access is blocked through the binding of the bis-cyclam amine (-NH) groups with the negatively charged carboxyl groups of aspartate and glutamate residues of the CXCR4 receptor [11]. The detailed understanding of the virus entrance mechanism led to the development of novel cyclam-based antivirals [12]. Tetraazamacrocycles and their metal complexes have also been studied as antimalarial [13,14], antischistosomal [15], as well as antileishmanial drugs [16]. Furthermore, the latter compounds have been investigated as anticancer agents [17]. In this context, a Zn2+ tetraazamacrocycle complex exhibiting a considerable cytotoxicity towards human breast, cervical, and lung cancer cell lines was recently described [18]. The interaction with DNA suggests that the mechanism of apoptotic induction may be distinct from that of cisplatin [18]. On the other hand, the antibacterial properties of cyclams and cyclens are scarcely reported, being their activity against Mycobacterium tuberculosis the principal focus of interest [19,20]. In a recent work, we have shown that the cyclam salt [H2{H2(4-CF3PhCH2)2Cyclam}](CH3COO)2.(CH3COOH)2 has antimicrobial activity against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. Furthermore, this compound was also found to be active against selected fungal strains of the Candida genus, with modest minimal inhibitory concentration (MIC) values [21]. These results, together with the fact that cyclams and cyclens represent a highly versatile backbone, which is easily modifiable by the introduction of new chemical substituents at the amino groups, highlight these molecules as a potential new family of antimicrobials.
In the present work, we describe novel cyclam and cyclen derivatives, specifically designed to investigate the relationships between structure and antibacterial activity, with the overall objective of improving the antibacterial properties of these molecules.

2. Results and Discussion

The monosubstituted cyclam salt, 5, was synthesized according to a procedure that involves the protection of three of the four nitrogen atoms of the cyclam ring in order to selectively functionalize only one of them. As so, protection was done using tert-butyloxycarbonyl (Boc) groups through the reaction of cyclam, 1, with three equiv. of Boc2O (see Scheme 1). This procedure was already reported in the literature to give the trisubstituted derivative H(Boc)3Cyclam, 2 [22]. The alkylation of 2 with 4-(trifluoromethyl)benzyl bromide led to the formation of (4-CF3PhCH2)(Boc)3Cyclam, 3, which was converted into the chloride salt 5 after removal of all Boc protecting groups. Two pathways for the synthesis of 5 were explored: i) The reaction of 3 with trifluoracetic followed by neutralization with KOH to give the neutral compound 4, which was subsequently protonated with HCl; and ii) the direct reaction of 3 with HCl. The synthetic route for the preparation of [H4{H2(4-CF3PhCH2)Cyclam}]Cl4, 5, is presented in Scheme 1. The two procedures led essentially to the same overall yield of 5, which shows that the two-step path is not necessary if the cyclam salt is the desired product.
The 1H NMR spectrum of 5 reveals ten multiplets corresponding to the methylene protons of the macrocycle backbone integrating to two protons each, and one singlet that corresponds to the two benzylic protons of the pendant arm as a result of the C1 symmetry of the compound. In addition, two doublets integrating to two protons each appear in the aromatic region of the spectrum. The NH2+ protons are not observed in the D2O solution, in agreement with proton exchange. The 13C{1H} NMR spectrum of 5 displays ten different resonances for the macrocycle carbons and one signal for the benzylic carbon of the pendant arm, as expected. Additional resonances due to aromatic rings and the CF3 group are also present. Despite the overlapping of several resonances observed in the proton and carbon NMR spectra, their assignment was based on 2D NMR experiments (1H-1H COSY and 1H-13C HSQC). The 19F NMR spectrum shows a singlet due to the CF3 group at −62.6 ppm.
The preparation of trans-disubstituted cyclams of general formula H2Bn2Cyclam (Bn = PhCH2, 6, 4-CF3PhCH2, 7, 4-CH3PhCH2, 8, 4-CF3CH2PhCH2, 9, and 3-CF3PhCH2, 10) was attained through a standard procedure that involves the reaction of 1,4,8,11-tetraazatriciclo[9.3.1.14,8]hexadecane with 2 equiv. of the suitable benzyl bromide, followed by basic hydrolysis [23,24,25].
In the 1H NMR spectra of compounds 6–10, the macrocycle geminal protons are equivalent, giving rise to the emergence of only five signals integrating to four protons each. The methylene protons of the pendant arms show up as singlets in accordance with the fast nitrogen inversion that determines C2 symmetry in the solution. The 13C{1H} NMR spectra display five different resonances for the macrocycle backbone and one set of resonances that corresponds to the benzyl moieties. The proton and carbon NMR spectra of 6–10 are similar to those obtained for other trans-disubstituted cyclams already reported and do not deserve further comment [23,24,25].
Crystals of 8 suitable for single crystal X-ray diffraction were obtained from slow evaporation of a chloroform solution. Crystallographic and experimental details of data collection and crystal structure determination are presented in the experimental section. A Mercury diagram of the solid-state molecular structure of 8 is shown in Figure 1.
The solid-state molecular structure of 8 shows the two benzyl pendant arms located at opposite sides of the macrocyclic ring. Despite the structural arrangement of the cyclam ring, one cannot consider intramolecular hydrogen bonds between N(2)-H(2N) and N(1) as the corresponding angles are narrower than 110° [26]. These features were also observed in the previously reported solid-state molecular structure of H2(4-CNPhCH2)2Cyclam [25].
Compounds 6–10 were converted into the corresponding acetate salts (11–15) in high yields upon protonation of the two remaining NH groups of the macrocycles with acetic acid. The chloride and bromide salts (16–21) were obtained by the addition of concentrated aqueous solutions of HCl and HBr to ethanolic solutions of compounds 6–10, respectively. The latter compounds precipitate out of the solution in very high yields. The synthetic route for the preparation of compounds 6–21 is shown in Scheme 2.
The 1H NMR spectra of compounds 11–21 are similar to the ones described for the parent species 6–10 showing five multiplets corresponding to the methylene protons of the macrocycle backbone integrating to four protons each and one singlet that correspond to the four benzylic protons of the pendant arms. In addition, one set of resonances appears in the aromatic region of the spectra. In compounds 13 and 18, the protons of the CH3 groups show up as singlets at 2.32 and 1.37 ppm, respectively. In 14 and 19, the CH2CF3 groups appear as a quartet with 3JH-F = 11 Hz at 3.47 and 3.61 ppm, respectively. The NH2+ and COOH protons are absent in D2O solutions due to fast proton exchange. The 13C{1H} NMR spectra of 11–21 are also similar to the ones described for 6–10 displaying five different resonances for the macrocycle and one for the benzylic carbon of the pendant arms, as expected. Additional resonances due to aromatic rings are also present.
Crystals of 14 suitable for single crystal X-ray diffraction were obtained by the concentration of an aqueous acetic acid solution. The asymmetric unit of 14 displays two molecules (14a and 14b). Crystallographic and experimental details of the data collection and crystal structure determination are presented in the experimental section. The solid-state molecular structure of 14b is presented in Figure 2. It shows two mutually trans-benzyl pendant arms pointing to opposite sides of the macrocyclic ring. The structural arrangement of 14 reveals the establishment of hydrogen bonds between the acetate anions, the cyclam framework, and co-crystallized acetic acid molecules. Detailed hydrogen bond lengths and angles are presented in Table S1 as Supporting Information. Each [CH3COO…HOOCCH3]− pair is located on opposite sides of the plane that contains the four nitrogen atoms of the cyclam ring. Such interactions are not present in the solution as revealed by the C2 symmetry observed in the NMR spectra. The solid-state molecular structure of 14 reveals similar features to those observed for [H2{H2(4-CF3PhCH2)2Cyclam}](CH3COO)2·(CH3COOH)2, 12, as previously reported [21].
The protonation of cyclam with HCl leads to the production of chloride salt [H4(H4Cyclam)]Cl4, 22, in a very high yield (see Scheme 3).
The NMR spectra of 22 are consistent with a tetraprotonated cyclam salt revealing only three resonances in both the proton and carbon spectra that correspond to the CH2 groups of the [C2] and [C3] chains of the cyclam ring.
The trans-disubstituted cyclen 24 was prepared by reaction of the bisaminal cyclen derivative 23 with 2 equiv. of 4-CF3PhCH2Br, followed by hydrazinolysis using hydrazine monohydrate. The corresponding chloride salt 25 was obtained by protonation of the neutral cyclen species 24 with a concentrated aqueous solution of HCl, as presented in Scheme 4.
The NMR spectra of 24 and 25 are similar showing the typical pattern for a trans-disubstituted cyclen. The 1H NMR spectra show two multiplets corresponding to the methylene protons of the macrocycle backbone integrating to eight protons each and one singlet that correspond to the four benzylic protons of the pendant arms. In addition, two doublets appear in the aromatic region of the spectra. The 13C{1H} NMR spectra of both compounds display two different resonances for the macrocycle and one for the benzylic carbon of the pendant arms, as expected. Additional resonances due to the aromatic ring carbons and the CF3 group are also present. The 19F NMR spectra of 24 and 25 show a singlet due to the CF3 groups at −62.5 and −59.8 ppm, respectively.
The structure/antibacterial activity relationships of cyclam salts 5, 11–22, and 25 were assessed based on the determination of the MIC values of the compounds towards E. coli ATCC 25922 and S. aureus Newman. The results obtained for both bacteria are presented in Table 1.
The results presented in Table 1 show that in general the counter anion did not significantly affect the antibacterial activity of the compounds, and presented similar MIC values, as evidenced by sets 14/19, 15/20, and 12/17/21. The minor variations observed most probably result from the different molecular mass of acetate and chloride. This effect is more evident on the pair 17/21, with 21 exhibiting slightly higher MIC values most probably because of the higher molecular mass of bromine. An exception to these general observations was detected for the pairs 11/16 and 13/18. In those cases, the cyclam derivative has apolar pendant arms and the discrepancies observed for the MIC values of the acetate and chloride salts might result from additional unknown factors dependent on the strain under study. Such observations are more pronounced for S. aureus than for E. coli, and might reflect the distinct and specific mechanisms used by each bacterial species to cope with antimicrobials.
The results in Table 1 also evidence the effect of the number of pendant arms on the antibacterial activity of cyclam derivatives: MIC values higher than 512 µg/mL were estimated for the monosubstituted cyclam 5, while MIC values of 7.3 and 4.3 µg/mL were registered for the disubstituted cyclam derivative 17 towards S. aureus and E. coli, respectively.
We also investigated the effect of the distance of the trifluoromethyl group attached to the aromatic ring of the macrocyclic pendant arm on the antibacterial activity of the compound. The results in Table 1 show that the insertion of one CH2 spacer between the trifluoromethyl group and the aromatic ring led to a slight reduction in the antibacterial activity of cyclam derivatives (see pairs 12/14 and 17/19). The decrease in antimicrobial activity may have either an electronic or stereochemical origin. The inclusion of a CH2 spacer has a strong influence on the relative position of the CF3 group towards a possible acceptor fragment, and thus, it is expected to modify the interaction between both fragments. Additionally, the CH2 spacer blocks the electronic delocalization that is present if the CF3 group is directly bonded to the aromatic ring. The importance of the substitution pattern of the phenyl ring is also attested by the comparison of antibacterial properties of the meta- and para-CF3 cyclam pending groups (see pairs 12/15 and 17/20). One may thus conclude that the antibacterial activity is ruled by subtle electronic interactions between the molecule and the receptor [27,28]. In line with these considerations, the results in Table 1 show that the polarity of the substituent on the aromatic ring of the macrocyclic pendant arm is critical for the antimicrobial activity of the compounds. Cyclam derivatives with the polar CF3 substituents present higher antibacterial activities than those with the apolar CH3 substituents (see MIC values of pairs 12/13 and 17/18).
The analogous cyclen species 25 presents a lower antimicrobial activity. This result suggests that the size of the macrocyclic backbone is an important feature for the antimicrobial activity of the tetraazamacrocycles, although strong conclusions cannot be taken on this subject due to the limited number of compounds tested.

3. Materials and Methods

3.1. General Considerations

Compounds 1 [29], 2 [22], 6 [23], 7 [24], 12 [21], 23 [30], and 1,4,8,11-tetraazatriciclo[9.3.1.14,8]hexadecane [23] were prepared according to published procedures. All other reagents were commercial grade and used without further purification. NMR spectra were recorded in a Bruker AVANCE II 300 or 400 MHz spectrometer, at 296 K unless stated otherwise, referenced internally to residual proton-solvent (1H) or solvent (13C) resonances, and reported relative to tetramethyl silane (0 ppm). 19F NMR was referenced to external CF3COOH (−76.55 ppm). 1H-13C{1H} HSQC and 1H-1H COSY NMR experiments were performed in order to perform all the assignments. Elemental analyses were obtained from Laboratório de Análises do IST.

3.2. Synthetic Procedures

Boc3(4-CF3PhCH2)Cyclam (3): Compound 2 (1.02 g, 2.04 mmol) was dissolved in a minimum volume of dimethylformamide. K2CO3 (0.70 g, 5.06 mmol) and 4-(trifluoromethyl)benzyl bromide (0.49 g, 2.05 mmol) were added. The reaction mixture was left stirring overnight. A saturated solution of KHCO3 and brine were added, and the product extracted with small portions of chloroform. The organic phases were combined and dried with anhydrous MgSO4. After filtration, the solvent was evaporated under reduced pressure and the product was obtained in a 98% yield (1.32 g, 2.00 mmol). 1H NMR (CDCl3, 300.1 MHz, 296 K): δ (ppm) 7.50 (d, 3JH-H = 8 Hz, 2H, o-Ph or m-Ph), 7.34 (d, 3JH-H = 8 Hz, 2H, o-Ph or m-Ph), 3.53 (s, 2H, PhCH2N), 3.30 (overlapping, 12H total, 6H, [C3]CH2N and 6H, [C2]CH2N), 2.56 (m, 2H [C2]CH2N), 2.34 (m, 2H [C3]CH2N), 1.84 (m, 2H, CH2CH2CH2), 1.65 (m, 2H, CH2CH2CH2), 1.41-1.21 (br, 27H, CH3). 13C{1H} NMR (CDCl3, 75.5 MHz, 296 K): δ (ppm) 155.8 (CO), 155.6 (overlapping, CO), 143.4 (i-Ph), 129.2 (o-Ph or m-Ph), 127.4 (q, 2JC-F = 97 Hz, p-Ph), 125.2 (o-Ph or m-Ph), 124.3 (q, 1JC-F = 272 Hz, CF3), 79.7 (C(CH3)3), 79.6 (C(CH3)3), 79.5 (C(CH3)3), 59.5 (PhCH2N), 53.5 ([C2]CH2N), 51.9 ([C3]CH2N), 47.9-46.3 (overlapping, [C2]CH2N and [C3]CH2N), 28.5-28.4 (overlapping, CH2CH2CH2 and CH3). 19F NMR (CDCl3, 282.4 MHz, 296K): δ (ppm) −62.4 (s, CF3). MS (CH3CN, ESI): m/z 659.21 [M+H]+, 501.20 [M-CF3PHCH2+H]+.
H3(4-CF3PhCH2)Cyclam (4): Compound 3 (0.66 g, 1.00 mmol) was dissolved in 20 mL of dichloromethane and 10 mL of trifluoracetic acid (0.13 mol) were added. The reaction mixture was refluxed overnight. The solvent was evaporated to dryness to give a brow oil that was dissolved in water. KOH was added until the reaction mixture reached pH ≈ 13. The product was extracted with dichloromethane, the organic phase was washed with brine and dried with anhydrous MgSO4. After filtration, the solvent was evaporated to dryness producing the product as a white solid in a 31% yield (0.11 g, 0.31 mmol). 1H NMR (CDCl3, 400.1 MHz, 296 K): δ (ppm) 7.57 (d, 3JH-H = 8 Hz, 2H, m-Ph), 7.48 (d, 3JH-H = 8 Hz, 2H, o-Ph), 4.39 (br, 3H, NH) 3.65 (s, 2H, PhCH2N), 2.90 (m, 2H, [C2]CH2N), 2.85 (m, 2H [C3]CH2N), 2.79 (overlapping, 4H total, 2H, [C3]CH2N and 2H, [C2]CH2N), 2.71 (overlapping, 4H total, 2H, [C3]CH2N and 2H, [C2]CH2N), 2.60 (overlapping, 4H total, 2H, [C3]CH2N and 2H, [C2]CH2N), 1.89 (m, 2H, CH2CH2CH2), 1.81 (m, 2H, CH2CH2CH2). 13C{1H} NMR (CDCl3, 100.6 MHz, 296 K): δ (ppm) 142.8 (i-Ph), 129.7 (q, 2JC-F = 30 Hz, p-Ph), 129.6 (o-Ph), 127.0 (q, 1JC-F = 264 Hz, CF3), 125.5 (q, 3JC-F = 4 Hz, m-Ph), 57.9 (PhCH2N), 53.5 ([C2]CH2N or [C3]CH2N), 53.1 [C2]CH2N or [C3]CH2N), 50.5 ([C2]CH2N or [C3]CH2N), 49.3 ([C3]CH2N), 48.8 ([C2]CH2N or [C3]CH2N), 48.6 ([C2]CH2N or [C3]CH2N), 47.2 ([C2]CH2N or [C3]CH2N), 47.1 ([C2]CH2N), 27.0 (CH2CH2CH2), 25.6 (CH2CH2CH2). 19F NMR (CDCl3, 376.5 MHz, 296K): δ (ppm) −62.4 (s, CF3). Anal. calcd for C18H29F3N4: C, 60.31; H, 8.16; N, 15.63. Found: C, 60.28; H, 8.19; N, 15.57.
[H4{H3(4-CF3PhCH2)Cyclam}]Cl4 (5): Method A: Compound 3 (0.66 g, 1.00 mmol) was dissolved in dichloromethane and a concentrated aqueous solution of HCl (37%) was added until pH ≈ 1. The reaction mixture was left stirring overnight at room temperature. The solvent was evaporated to dryness producing the product as white solid in 56% yield (0.29 g, 0.56 mmol). Method B: Compound 4 (0.11 g, 0.31 mmol) was dissolved in ethanol and a concentrated aqueous solution of HCl (37%) was added until pH ≈ 1. The product was precipitated out of the solution. After filtration, the product was dried producing the compound as a white solid in a 48% yield (0.08 g, 0.15 mmol). 1H NMR (D2O/(CD3)2CO, 300.1 MHz, 296 K): δ (ppm) 7.87 (d, 3JH-H = 9 Hz, 2H, m-Ph), 7.78 (d, 3JH-H = 9 Hz, 2H, o-Ph), 4.48 (s, 2H, PhCH2N), 3.70 (m, 6H, [C2]CH2N), 3.59 (m, 2H [C2]CH2N), 3.50 (m, 6H, [C3]CH2N), 3.36 (m, 2H [C3]CH2N), 2.33 (m, 4H, CH2CH2CH2). 13C {1H} NMR (D2O/(CD3)2CO, 75.5 MHz, 296 K): δ (ppm) 135.1 (i-Ph), 131.8 (o-Ph), 131.2 (q, 2JC-F = 32 Hz, p-Ph), 126.4 (d, 3JC-F = 3 Hz, m-Ph), 124.2 (q, 1JC-F = 272 Hz, CF3), 57.4 (PhCH2N), 48.7 ([C3]CH2N), 46.3 ([C2]CH2N), 43.0 ([C3]CH2N), 42.5 (overlapping, [C3]CH2N), 39.5 (overlapping, [C2]CH2N), 39.1 ([C2]CH2N), 20.0 (CH2CH2CH2), 19.7 (CH2CH2CH2). 19F NMR (D2O/(CD3)2CO, 282.4 MHz, 296K): δ (ppm) −62.6 (s, CF3). Anal. calcd for C18H33Cl4F3N4.H2O: C, 41.39; H, 6.75; N, 10.73. Found: C, 41.29; H, 6.60; N, 10.68.
H2(4-CH3PhCH2)2Cyclam (8): 1,4,8,11-tetraazatriciclo[9.3.1.14,8]hexadecane (5.00 g, 22.3 mmol) was dissolved in a minimum volume of acetonitrile and 2.2 equiv. of 4-(methyl)benzyl bromide (9.10 g, 49.2 mmol) were added. The solution was stirred overnight at room temperature resulting in a white precipitate that was filtered, washed with acetonitrile, and dried under reduced pressure. A portion of the product obtained was hydrolyzed in an aqueous NaOH solution (3M) for 4 h under stirring at room temperature. The product was extracted with small portions of chloroform that were combined and dried with anhydrous MgSO4. After filtration, the solvent was evaporated to dryness giving an oil that was converted into a white solid after successive freeze–trituration–pump–thaw cycles. Compound 8 was obtained in a 92% yield (3.80 g, 9.30 mmol). Suitable crystals for single crystal X-ray diffraction were obtained from a concentrated chloroform solution. 1H NMR (CDCl3, 400.1 MHz, 296 K): δ (ppm) 7.19 (d, 3JH-H = 8 Hz, 4H, o-Ph or m-Ph), 7.10 (d, 3JH-H = 8 Hz, 4H, o-Ph or m-Ph), 3.69 (s, 4H, PhCH2N), 2.79 (s, 2H, NH), 2.73 (m, 4H, [C3]CH2N), 2.69 (m, 4H, [C2]CH2N), 2.55 (m, 4H, [C2]CH2N), 2.51 (m, 4H, [C3]CH2N), 2.29 (s, 6H, CH3), 1.83 (m, 4H, CH2CH2CH2). 13C {1H} NMR (CDCl3, 100.6 MHz, 296 K): δ (ppm) 136.6 (i-Ph or p-Ph), 134.2 (i-Ph or p-Ph), 129.7 (o-Ph or m-Ph), 128.9 (o-Ph or m-Ph), 57.5 (PhCH2N), 54.2 ([C2]CH2N), 51.8 ([C3]CH2N), 50.5 ([C3]CH2N), 47.9 ([C2]CH2N), 26.1 (CH2CH2CH2), 21.8 (CH3). Anal. calcd for C26H40N4: C, 76.42; H, 9,87; N, 13.71. Found: C, 76.06; H, 9.91; N, 13.69.
H2(4-CF3CH2PhCH2)2Cyclam (9): Compound 9 was prepared by the same procedure described for 8 by reaction of 1,4,8,11-tetraazatriciclo[9.3.1.14,8]hexadecane with 1-(bromomethyl)-4-(2,2,2-trifluoroethyl)benzene being obtained as a white solid in a 52% yield (0.28 g, 0.51 mmol). 1H NMR (CDCl3, 400.1 MHz, 296 K): δ (ppm) 7.29 (d, 3JH-H = 8 Hz, 4H, o-Ph or m-Ph), 7.21 (d, 3JH-H = 8 Hz, 4H, o-Ph or m-Ph), 3.71 (s, 4H, PhCH2N), 3.31 (q, 4H, 3JH-F = 11 Hz, CH2CF3), 2.72-2.53 (overlapping, 18H total, 2H, NH, 8H, [C3]CH2N and 8H, [C2]CH2N), 1.83 (m, 4H, CH2CH2CH2). 13C{1H} NMR (CDCl3, 100.6 MHz, 296 K): δ (ppm) 137.6 (i-Ph), 130.1 (o-Ph or m-Ph), 129.9 (o-Ph or m-Ph), 129.0 (p-Ph), 125.9 (q, 1JC-F = 279 Hz, CH2CF3), 57.6 (PhCH2N), 54.3 ([C2]CH2N), 51.7 ([C3]CH2N), 50.1 ([C2]CH2N or [C3]CH2N), 47.9 ([C2]CH2N or [C3]CH2N), 40.0 (q, 2JH-F = 29 Hz, CH2CF3), 26.1 (CH2CH2CH2). 19F NMR (CDCl3), 376.5 MHz, 296K): δ (ppm) −65.9 (s, CF3). Anal. calcd for C28H38F6N4: C, 61.75; H, 7.03; N, 10.29. Found: C, 60.82; H, 6.75; N, 10.00.
H2(3-CF3PhCH2)2Cyclam (10): Compound 10 was prepared by the same procedure described for 8 by reaction of 1,4,8,11-tetraazatriciclo[9.3.1.14,8]hexadecane with 1-(bromomethyl)-3-(trifluoromethyl)benzene being obtained as a white solid in a 61% yield (2.55 g, 4.94 mmol). 1H NMR (CDCl3, 400.1 MHz, 296 K): δ (ppm) 7.55 (s, 2H, o-Ph), 7.49-7.44 (overlapping, 4H total, o-Ph and m-Ph), 7.37 (d, 3JH-H = 8 Hz, 2H, p-Ph), 3.68 (s, 4H, PhCH2N), 2.74-2.69 (overlapping, 10H total, 2H, NH, 4H, [C3]CH2N and 4H, [C2]CH2N), 2.59 (m, 4H, [C2]CH2N), 2.51 (m, 4H, [C3]CH2N), 1.83 (m, 4H, CH2CH2CH2). 13C{1H} NMR (CDCl3, 100.6 MHz, 296 K): δ (ppm) 139.3 (i-Ph), 132.6 (o-Ph or m-Ph), 130.6 (q, 2JC-F = 32 Hz, m-Ph), 128.7 (o-Ph or m-Ph), 125.8 (q, 3JC-F = 3 Hz, o-Ph), 124.3, (q, 1JC-F = 273 Hz, CF3), 124.0 (q, 3JC-F = 4 Hz, p-Ph), 57.6 (PhCH2N), 53.9 ([C2]CH2N), 51.3 ([C3]CH2N), 49.1 ([C2]CH2N or [C3]CH2N), 47.5 ([C2]CH2N or [C3]CH2N), 25.9 (CH2CH2CH2). 19F NMR (CDCl3), 376.5 MHz, 296K): δ (ppm) −62.5 (s, CF3). Anal. calcd for C26H34F6N4: C, 60.45; H, 6.63; N, 10.85. Found: C, 60.21; H, 6.63; N, 10.82.
[H2{H2(PhCH2)2Cyclam}](CH3COO)2.(CH3COOH)2 (11): Compound 6 (0.35 g, 0.92 mmol) was dissolved in a small volume of acetonitrile and 1 mL of glacial acetic acid was added to the solution. This mixture was refluxed for 1 h and the solvent was evaporated under reduced pressure producing a white solid that was washed with diethyl ether and dried in a vacuum. The product was obtained as a white solid in an 84% yield (0.48 g, 0.77 mmol). 1H NMR (CDCl3, 400.1 MHz, 296 K): δ (ppm) 10.81 (overlapping, 6H total, 4H, NH2+ and 2H, CH3COOH), 7.31-7.30 (overlapping, 6H total, 2H, p-Ph and 4H, m-Ph), 7.21 (d, 3JH-H = 8 Hz, 4H, o-Ph), 3.97 (s, 4H, PhCH2N), 3.25 (m, 4H, [C3]CH2N), 3.20 (m, 4H, [C2]CH2N), 2.78 (m, 4H, [C2]CH2N), 2.74 (m, 4H, [C3]CH2N), 2.00-1.97 (overlapping, 16H total, 4H, CH2CH2CH2, 6H, CH3COO− and 6H, CH3COOH). 13C{1H} NMR (CDCl3,100.6 MHz, 296 K): δ (ppm) 176.5 (COO), 134.0 (i-Ph), 130.8 (o-Ph), 128.4 (m-Ph), 127.7 (p-Ph), 53.9 (PhCH2N), 51.9 ([C3]CH2N), 48.5 (overlapping, [C2]CH2N and [C3]CH2N), 45.4 ([C2]CH2N), 22.8 (CH2CH2CH2), 22.5 (CH3COO). Anal. calcd for C28H44N4O4.(CH3COOH)2: C, 61.91; N, 9.03; H, 8.44. Found: C, 61.85; N, 9.81; H, 8.40.
[H2{H2(4-CH3PhCH2)2Cyclam}](CH3COO)2.(CH3COOH)2 (13): Compound 13 was prepared by the same procedure described for 11 using compound 8 (1.00 g, 2.45 mmol) as the starting material. The product was obtained as a white solid in an 80% yield (1.27 g, 1.96 mmol). 1H NMR (D2O, 300.1 MHz, 296 K): δ (ppm) 7.31 (d, 3JH-H = 6 Hz, 4H, o-Ph or m-Ph), 7.23 (d, 3JH-H = 6 Hz, 4H, o-Ph or m-Ph), 3.48 (s, 4H, PhCH2N), 3.31 (m, 4H, [C3]CH2N or [C2]CH2N), 3.23 (m, 4H, [C3]CH2N or [C2]CH2N), 2.80 (m, 4H, [C3]CH2N or [C2]CH2N), 2.76 (m, 4H, [C3]CH2N or [C2]CH2N), 2.25 (s, 6H, CH3), 1.99 (overlapping, 16H total, 4H, CH2CH2CH2, 6H, CH3COO- and 6H, CH3COOH). 1H NMR (CDCl3, 300.1 MHz, 296 K): δ (ppm) 10.73 (overlapping, 6H total, 4H, NH2+ and 2H, CH3COOH), 7.12 (d, 3JH-H = 6 Hz, 4H, o-Ph or m-Ph), 7.02 (d, 3JH-H = 9 Hz, 4H, o-Ph or m-Ph), 3.79 (s, 4H, PhCH2N), 3.16-3.14 (overlapping, 8H total, 4H, [C3]CH2N and 4H, [C2]CH2N), 2.75 (m, 4H, [C2]CH2N), 2.66 (m, 4H, [C3]CH2N), 2.32 (s, 6H, CH3), 1.99 (overlapping, 16H total, 4H, CH2CH2CH2, 6H, CH3COO- and 6H, CH3COOH). 13C{1H} NMR (CDCl3, 75.5 MHz, 296 K): δ (ppm) 176.6 (COO), 137.3 (i-Ph), 130.9 (p-Ph), 130.8 (o-Ph or m-Ph), 129.1 (o-Ph or m-Ph), 52.7 (PhCH2N), 51.3 ([C3]CH2N), 48.7 ([C2]CH2N), 48.3 ([C3]CH2N), 45.6 ([C2]CH2N), 22.8 (CH2CH2CH2), 22.6 (CH3COO), 21.2 (CH3). Anal. calcd for C30H48N4O4.(CH3COOH)2: C, 62.94; H,8.70; N,8.64. Found: C, 62.26; H, 9.17; N, 8.46.
[H2{H2(4-CF3CH2PhCH2)2Cyclam}](CH3COO)2.(CH3COOH)2 (14): Compound 14 was prepared by the same procedure described for 11 using compound 9 (0.24 g, 0.44 mmol) as the starting material. The product was obtained as a white solid in an 84% yield (0.29 g, 0.37 mmol). Suitable crystals for single crystal X-ray diffraction were obtained from an aqueous acetic acid solution. 1H NMR (D2O, 400.1 MHz, 296 K): δ (ppm) 7.46 (d, 3JH-H = 8 Hz, 4H, o-Ph or m-Ph), 7.35 (d, 3JH-H = 8 Hz, 4H, o-Ph or m-Ph), 3.60 (s, 4H, PhCH2N), 3.47 (q, 4H, 3JH-F = 11 Hz, CH2CF3), 3.33 ([C3]CH2N or [C2]CH2N), 3.28 (m, 4H, [C3]CH2N or [C2]CH2N), 2.83 (m, 4H, [C3]CH2N or [C2]CH2N), 2.73 (m, 4H, [C3]CH2N or [C2]CH2N), 1.99 (overlapping, 16H total, 4H, CH2CH2CH2, 6H, CH3COO- and 6H, CH3COOH). 1H NMR (CDCl3, 400.1 MHz, 296 K): δ (ppm) 10.28 (overlapping, 6H total, 4H, NH2+ and 2H, COOH), 7.25 (d, 3JH-H = 8 Hz, 4H, o-Ph or m-Ph), 7.16 (d, 3JH-H = 8 Hz, 4H, o-Ph or m-Ph), 3.83 (s, 4H, PhCH2N), 3.34 (m, 3JH-F = 11 Hz, 4H, CH2CF3), 3.10 (overlapping, 8H total, 4H, [C2]CH2N and 4H, [C3]CH2N), 2.76 (m, 4H, [C2]CH2N), 2.68 (m, 4H, [C3]CH2N), 2.00-1.96 (overlapping, 16H total, 4H, CH2CH2CH2, 6H, CH3COO- and 6H, CH3COOH). 13C{1H} NMR (CDCl3,100.6 MHz, 296 K): δ (ppm) 176.7 (COO), 134.6 (i-Ph), 131.0 (o-Ph or m-Ph), 130.2 (o-Ph or m-Ph), 129.6 (m, 3JC-F = 3 Hz, p-Ph), 125.8 (q, 1JC-F = 277 Hz, CH2CF3), 53.3 (PhCH2N), 51.1 ([C3]CH2N), 49.1 ([C2]CH2N), 48.2 ([C3]CH2N or [C2]CH2N), 45.9 ([C3]CH2N or [C2]CH2N), 40.0 (q, 2JH-F = 29 Hz, CH2CF3), 23.1 (CH2CH2CH2), 22.6 (CH3COO). 19F NMR (D2O, 376.5 MHz, 296 K): δ (ppm) −65.8 (s, CH2CF3). 19F NMR (CDCl3, 376.5 MHz, 296 K): δ (ppm) −65.9 (s, CH2CF3). Anal. calcd for C32H46F6N4O4.(CH3COOH)2: C, 55.09; H, 6.94; N, 7.14. Found: C, 55.00; H, 6.86; N, 7.01.
[H2{H2(3-CF3PhCH2)2Cyclam}](CH3COO)2.(CH3COOH)2 (15): Compound 15 was prepared by the same procedure described for 11 using compound 10 (0.55 g, 1.06 mmol) as the starting material. The product was obtained as a white solid in a 28% yield (0.23 g, 0.30 mmol). 1H NMR (D2O, 400.1 MHz, 296 K): δ (ppm) 7.70 (d, 3JH-H = 8 Hz, 2H, p-Ph), 7.65 (s, 2H, o-Ph), 7.62 (t, 3JH-H = 8 Hz, 2H, m-Ph), 7.56 (d, 3JH-H = 8 Hz, 2H, o-Ph), 3.70 (s, 4H, PhCH2N), 3.33-3.32 (overlapping, 8H total, 4H, [C3]CH2N and 4H, [C2]CH2N), 2.82 (m, 4H, [C2]CH2N), 2.69 (m, 4H, [C3]CH2N), 2.02 (m, 4H, CH2CH2CH2), 1.98 (overlapping, 12H total, 6H, CH3COO− and 6H, CH3COOH). 1H NMR (CDCl3, 300.1 MHz, 296 K): δ (ppm) 10.61 (overlapping, 6H total, 4H, NH2+ and 2H, COOH), 7.54 (d, 3JH-H = 8 Hz, 2H, p-Ph), 7.44 (t, 3JH-H = 8 Hz, 2H, m-Ph), 7.39 (s, 2H, o-Ph), 7.36 (d, 3JH-H = 8 Hz, 2H, o-Ph), 3.90 (s, 4H, PhCH2N), 3.13 (overlapping, 8H total, 4H, [C2]CH2N and 4H, [C3]CH2N), 2.77 (m, 4H, [C2]CH2N), 2.67 (m, 4H, [C3]CH2N), 2.00 (overlapping, 16H total, 4H, CH2CH2CH2, 6H, CH3COO− and 6H, CH3COOH). 13C{1H} NMR (CDCl3, 75.5 MHz, 296 K): δ (ppm) 176.7 (COO), 135.5 (o-Ph), 134.1 (i-Ph), 130.7 (q, 2JC-F = 32 Hz, m-Ph), 128.9 (m-Ph), 127.0 (q, 3JC-F = 4 Hz, o-Ph), 124.5 (q, 3JC-F = 4 Hz, p-Ph), 124.2 (q, 1JC-F = 272 Hz, CF3), 52.8 (PhCH2N), 51.3 ([C3]CH2N), 48.8 ([C2]CH2N), 48.5 ([C3]CH2N or [C2]CH2N), 46.0 ([C3]CH2N or [C2]CH2N), 23.0 (CH2CH2CH2), 22.5 (CH3COO). 19F NMR (D2O, 376.5 MHz, 296 K): δ (ppm) −62.4 (s, CF3). 19F NMR (CDCl3, 282.4 MHz, 296 K): δ (ppm) −62.6 (s, CF3). Anal. calcd for C30H42F6N4O4.(CH3COOH)2: C, 53.96; H, 6.66; N, 7.40. Found: C, 53.85; H, 6.74; N, 7.46.
[H4{H2(PhCH2)2Cyclam}]Cl4 (16): Compound 6 (1.00 g, 2.63 mmol) was dissolved in a minimum volume of ethanol and a concentrated aqueous solution of HCl (37%) was added dropwise until the solution reached pH ≈ 1. The white precipitate which formed was filtered, washed with ethanol, and dried under reduced pressure giving the product in a 51% yield (0.73 g, 1.34 mmol). 1H NMR (D2O/(CD3)2CO, 300.1 MHz, 296 K): δ (ppm) 7.57 (overlapping, 10H total, Ph), 4.50 (s, 4H, PhCH2N), 3.68-3.44 (overlapping, 16H total, 8H, [C3]CH2N and 8H, [C2]CH2N), 1.19 (m, 4H, CH2CH2CH2). 13C{1H} NMR (D2O/(CD3)2CO, 75.5 MHz, 296 K): δ (ppm) 131.2 (o-Ph or m-Ph), 129.7 (p-Ph), 129.5 (o-Ph or m-Ph), 129.2 (i-Ph), 57.3 (PhCH2N), 47.2 ([C2]CH2N), 44.7 ([C2]CH2N), 42.1 ([C3]CH2N), 37.5 ([C3]CH2N), 17.5 (CH2CH2CH2). Anal. calcd for C24H40Cl4N4.H2O: C, 52.95; H, 7.78; N, 10.29. Found: C, 52.78; H, 7.64; N, 10.25.
[H4{H2(4-CF3PhCH2)2Cyclam}]Cl4 (17): Compound 17 was prepared by the same procedure described for 16 using compound 7 (1.00 g, 1.94 mmol) as the starting material. The product was obtained as a white solid in a 66% yield (0.88 g, 1.29 mmol). 1H NMR (D2O/(CD3)2CO, 400.1 MHz, 296 K): δ (ppm) 7.85 (d, 3JH-H = 8 Hz, 4H, m-Ph), 7.75 (d, 3JH-H = 8 Hz, 4H, o-Ph), 4.24 (s, 4H, PhCH2N), 3.65 (m, 4H, [C2]CH2N), 3.51 (m, 4H, [C3]CH2N), 3.42 (m, 4H, [C2]CH2N), 3.20 (m, 4H, [C3]CH2N), 2.28 (m, 4H, CH2CH2CH2). 13C{1H} NMR (D2O/(CD3)2CO, 100.6 MHz, 296 K): δ (ppm) 136.2 (i-Ph), 131.7 (o-Ph), 130.8 (q, 2JC-F = 24 Hz, p-Ph), 126.3 (d, 3JC-F = 3 Hz, m-Ph), 124.3 (q, 1JC-F = 272 Hz, CF3), 57.1 (PhCH2N), 49.8 ([C3]CH2N), 47.7 ([C2]CH2N), 44.9 ([C3]CH2N), 41.2 ([C2]CH2N), 20.4 (CH2CH2CH2). 19F NMR (CDCl3, 376.5 MHz, 296 K): δ (ppm) −62.6 (s, CF3). Anal. calcd for C26H38Cl4F6N4.H2O: C, 45.90; H, 5.93; N, 8.23. Found: C, 46.01; H, 5.80; N, 8.23.
[H4{H2(4-CH3PhCH2)2Cyclam}]Cl4 (18): Compound 18 was prepared by the same procedure described for 16 using compound 8 (0.80 g, 1.96 mmol) as the starting material. The product was obtained as a white solid in an 88% yield (0.99 g, 1.73 mmol). 1H NMR (D2O/C6D5N, 300.1 MHz, 296 K): δ (ppm) 6.51(d, 3JH-H = 6 Hz, 4H, o-Ph or m-Ph), 6.51 (d, 3JH-H = 6 Hz, 4H, o-Ph or m-Ph), 2.92 (m, 4H, [C3]CH2N), 2.83 (overlapping, 8H total, 4H, [C2]CH2N and 4H, PhCH2N), 2.09 (m, 4H, [C2]CH2N), 1.96 (m, 4H, [C3]CH2N), 1.42 (m, 4H, CH2CH2CH2) 1.37 (s, 6H, CH3). 13C{1H} NMR (D2O/C6D5N, 75.5 MHz, 296 K): δ (ppm) 139.9 (i-Ph), 133.2 (p-Ph), 132.7 (o-Ph or m-Ph), 131.6 (o-Ph or m-Ph), 57.3 ([C3]CH2N), 53.9 ([C3]CH2N), 53.0 ([C2]CH2N), 50.9 (PhCH2N), 47.5 ([C2]CH2N), 24.2 (CH2CH2CH2), 22.7 (CH3). Anal. calcd for C26H44Cl4N4.H2O: C, 54.55; H, 8.10; N, 9.79. Found: C, 54.41; H, 8.30; N, 9.57.
[H4{H2(4-CF3CH2PhCH2)2Cyclam}]Cl4 (19): Compound 19 was prepared by the same procedure described for 16 using compound 9 (0.35 g, 0.64 mmol) as the starting material. The product was quantitatively obtained as a white solid. 1H NMR (D2O/(CD3)2CO, 300.1 MHz, 296 K): δ (ppm) 7.63 (d, 3JH-H = 8 Hz, 4H, o-Ph or m-Ph), 7.57 (d, 3JH-H = 8 Hz, 4H, o-Ph or m-Ph), 4.41 (s, 4H, PhCH2N), 3.73-3.60 (overlapping, 12H total, 8H, [C2]CH2N and 4H, 3JH-F = 11 Hz, CH2CF3), 3.52 (m, 4H, [C3]CH2N), 3.42 (m, 4H, [C3]CH2N), 2.33 (m, 4H, CH2CH2CH2). 13C{1H} NMR (D2O/(CD3)2CO, 75.5 MHz, 296 K): δ (ppm) 132.8 (i-Ph), 131.6 (o-Ph or m-Ph), 131.5 (p-Ph and o-Ph or m-Ph), 126.4 (q, 1JC-F = 277 Hz, CH2CF3), 58.2 (PhCH2N), 48.6 ([C3]CH2N), 45.2 ([C2]CH2N), 42.4 ([C3]CH2N), 39.0 (q, 2JC-F = 29 Hz, CH2CF3), 38.2 ([C2]CH2N), 19.2 (CH2CH2CH2). 19F NMR (D2O/(CD3)2CO, 282.4 MHz, 296 K): δ (ppm) −65.6 (s, CH2CF3). Anal. calcd for C28H42Cl4F6N4.(H2O)2: C, 46.29; N, 7.71; H, 6.38. Found: C, 46.29; N, 747; H, 6.24.
[H4{H2(3-CF3PhCH2)2Cyclam}]Cl4 (20): Compound 20 was prepared by the same procedure described for 16 using compound 10 (0.70 g, 1.36 mmol) as the starting material. The product was obtained as a white solid in a 68% yield (0.61 g, 0.92 mmol). 1H NMR (D2O/(CD3)2CO, 300.1 MHz, 296 K): δ (ppm) 7.93-7.92 (overlapping, 8H total, Ph), 4.25 (s, 4H, PhCH2N), 3.76 (m, 4H, [C2]CH2N), 3.70 (m, 4H, [C3]CH2N), 3.28 (m, 4H, [C2]CH2N), 3.09 (m, 4H, [C3]CH2N), 2.38 (m, 4H, CH2CH2CH2). 13C{1H} NMR (D2O/(CD3)2CO, 75.5 MHz, 296 K): δ (ppm) 128.4 (i-Ph), 128.1 (o-Ph or m-Ph), 123.9 (q, 2JC-F = 32 Hz, m-Ph), 123.3 (o-Ph or m-Ph), 121.4 (q, 1JC-F = 270 Hz, CF3), 120.4 (q, 3JC-F = 3 Hz, o-Ph or p-Ph), 118.6 (q, 3JC-F = 4 Hz, o-Ph or p-Ph), 48.8 (PhCH2N), 44.0 ([C3]CH2N), 42.1 ([C2]CH2N), 39.7 ([C3]CH2N), 36.9 ([C2]CH2N), 15.3 (CH2CH2CH2). 19F NMR (D2O/(CD3)2CO, 282.4 MHz, 296 K): δ (ppm) -59.8 (s, CF3). Anal. calcd for C26H38Cl4F6N4: C, 47.14; H, 5.78; N, 8.46. Found: C, 46.51; H, 5.78; N, 8.40.
[H4{H2(4-CF3PhCH2)2Cyclam}]Br4 (21): Compound 7 (0.70 g, 1.36 mmol) was dissolved in a minimum volume of ethanol and a concentrated aqueous solution of HBr (48%) was added dropwise until the solution reached pH ≈ 1. The white precipitate which formed was filtered, washed with ethanol, and dried under reduced pressure giving the product in a 71% yield (0.84 g, 0.96 mmol). 1H NMR (D2O/(CD3)2CO, 300.1 MHz, 296 K): δ (ppm) 7.83 (d, 3JH-H = 8 Hz, 4H, m-Ph), 7.72 (d, 3JH-H = 8 Hz, 4H, o-Ph), 4.19 (s, 4H, PhCH2N), 3.63 (m, 4H, [C3]CH2N), 3.50 (m, 4H, [C3]CH2N), 3.37 (m, 4H, [C2]CH2N), 3.16 (m, 4H, [C2]CH2N), 2.21 (m, 4H, CH2CH2CH2). 13C{1H} NMR (D2O/(CD3)2CO, 75.5 MHz, 296 K): δ (ppm) 135.4 (i-Ph), 131.4 (o-Ph), 131.0 (q, 2JC-F = 33 Hz, p-Ph), 126.2 (m-Ph), 124.2 (q, 1JC-F = 273 Hz, CF3), 57.4 (PhCH2N), 49.2 ([C2]CH2N), 46.7 ([C2]CH2N or [C3]CH2N), 43.9 ([C2]CH2N or [C3]CH2N), 40.1 ([C3]CH2N), 19.8 (CH2CH2CH2). 19F NMR (CDCl3, 282.4 MHz, 296 K): δ (ppm) −62.6 (s, CF3). Anal. calcd for C26H38Br4F6N4.(H2O)2: C, 35.64; H, 4.83; N, 6.39. Found: C, 35.73; H, 4.82; N, 6.13.
[H4(H4Cyclam)]Cl4 (22): Compound 22 was prepared by the same procedure described for 16 using cyclam (0.59 g, 2.94 mmol) as the starting material. The product was obtained as a white solid in an 89% yield (1.00 g, 2.62 mmol). 1H NMR (D2O/(CD3)2CO, 400.1 MHz, 296 K): δ (ppm) 3.59 (m, 8H, [C2]CH2N), 3.44 (m, 8H, [C3]CH2N), 2.25 (m, 4H, CH2CH2CH2). 13C{1H} NMR (D2O/(CD3)2CO, 100.6 MHz, 296 K): δ (ppm) 40.5 ([C3]CH2N), 37.3 ([C2]CH2N), 17.6 (CH2CH2CH2). Anal. calcd for C10H28Cl4N4.(H2O)2: C, 31.43; H, 8.44; N, 14.66. Found: C, 31.34; H, 7.59; N, 14.56.
H2(4-CF3PhCH2)2Cyclen (24): Compound 23 (0.40 g, 2.06 mmol) was dissolved in the minimum volume of acetonitrile and two equiv. of 4-(trifluoromethyl)benzyl bromide (1.03 g, 4.31 mmol) were added. The solution was stirred overnight at room temperature. The white precipitate which formed was then separated by filtration, washed with acetonitrile, and dried under reduced pressure. The obtained product was heated overnight at 100 ºC in a 5 mL of hydrazine hydrate solution (50%–60%). The mixture was allowed to cool to room temperature and then placed in a cold bath to promote precipitation. The precipitate was filtered off, washed with ethanol, and dried in a vacuum giving compound 24 in a 45% yield (0.45 g, 0.92 mmol). 1H NMR (CDCl3, 300.1 MHz, 296 K): δ (ppm) 7.60 (d, 3JH-H = 8 Hz, 4H, m-Ph), 7.45 (d, 3JH-H = 8 Hz, 4H, o-Ph), 3.69 (s, 4H, PhCH2N), 2.69-2.65 (overlapping, 18H total, 16H, CH2N and 2H, NH). 13C{1H} NMR (CDCl3, 75.5 MHz, 296 K): δ (ppm) 143.4 (i-Ph), 129.8 (q, 2JC-F = 32 Hz, p-Ph), 129.3 (o-Ph), 125.6 (q, 3JC-F = 4 Hz, m-Ph), 124.2 (q, 1JC-F = 272 Hz, CF3), 60.1 (PhCH2N), 52.1 (CH2N), 45.7 (CH2N). 19F NMR (CDCl3, 282.4 MHz, 296 K): δ (ppm) −62.5 (s, CF3). Anal. Calcd. for C24H30F6N4.½H2O: C, 57.94; H, 6.28; N, 11.26. Found: C, 57.70; H, 6.32; N, 11.52.
H4[H2(4-CF3PhCH2)2Cyclen]Cl4 (25): Compound 24 (0.43 g, 0.88 mmol) was dissolved in a minimum volume of ethanol and a concentrated aqueous solution of HCl (37%) was added dropwise until the solution reached pH ≈ 1. The brown suspension was centrifugated giving a precipitate that was washed several times with small portions of acetonitrile and diethyl ether and further dried under reduced pressure. Compound 25 was obtained as a yellow solid in a 48% yield (0.27 g, 0.42 mmol). 1H NMR (D2O/(CD3)2CO, 300.1 MHz, 296 K): δ (ppm) 7.87 (d, 3JH-H = 8 Hz, 4H, m-Ph), 7.75 (d, 3JH-H = 8 Hz, 4H, o-Ph), 4.14 (s, 4H, PhCH2N), 3.50 (m, 8H CH2N), 3.12 (m, 8H CH2N). 13C{1H} NMR (D2O/(CD3)2CO, 75.5 MHz, 296 K): δ (ppm) 140.0 (i-Ph), 131.1 (o-Ph), 129.8 (q, 2JC-F = 32 Hz, p-Ph), 126.0 (q, 3JC-F = 4 Hz, m-Ph), 124.6 (q, 1JC-F = 271 Hz, CF3), 56.7 (PhCH2N), 47.8 (CH2N), 42.9 (CH2N). 19F NMR (D2O/(CD3)2CO, 282.4 MHz, 296 K): δ (ppm) −59.8 (s, CF3). Anal. Calcd. for C24H34Cl4F6N4: C, 45.44; H, 5.40; N, 8.83. Found: C, 46.04; H, 5.92; N, 10.70.

3.3. General Procedures for X-ray Crystallography

Crystallographic and experimental details of data collection and crystal structure determinations for the compounds are available in Table S2. Suitable crystals of compounds 8 and 14 were coated and selected in Fomblin® oil. Data were collected using graphite monochromated Mo-Kα radiation (λ = 0.71073 Å) on a Bruker AXS-KAPPA APEX II diffractometer. Cell parameters were retrieved using Bruker SMART software and refined using Bruker SAINT on all observed reflections [31]. Absorption corrections were applied using SADABS [32]. The structures were solved by direct methods using SIR97 [33]. Structure refinement was done using SHELXL [34], included in the WINGX-Version 1.80.01 [35] system of programs. The hydrogen atoms of the NH and COOH groups were located in the electron density maps. The other hydrogen atoms were inserted in calculated positions and allowed to refine in the parent atoms. Torsion angles, mean square planes, and other geometrical parameters were calculated using SHELX [34]. Illustrations of the molecular structures were made with Mercury CSD 3.9 for Windows [36]. Data for the structures of compounds 8 and 14 were deposited in CCDC under the deposit numbers 1920400 and 1920401, respectively, and can be obtained free of charge from The Cambridge Crystallographic Data Centre via http://www.ccdc.cam.ac.uk/conts/retrieving.html.

3.4. Minimal Inhibitory Concentration Assays

Escherichia coli ATCC 25922 and Staphylococcus aureus Newman are human clinical isolates and were maintained in Lennox broth (LB) solid medium. Minimal inhibitory concentration (MIC) assays were performed in Mueller–Hinton broth (MHB; Becton, Dickinson and Company) using a microdilution assay, based on previously described methods [21,37]. Briefly, bacterial cultures freshly grown in MBH solid medium contained in Petri plates were transferred into MHB liquid medium and grown for 4–5 hours with orbital agitation (250 rpm) at 37 °C. The cultures were then adequately diluted in fresh MHB to obtain approximately 106 colony forming units (CFUs) per mL. Adequate volumes of these cultures were used to inoculate approximately 5 × 105 CFUs per mL in 96-well polystyrene microtiter plates containing 100 μL of MHB supplemented with different concentrations of each compound under study, achieved by 1:2 serial dilutions ranging 512 μg/mL to 0.5 μg/mL. Compounds were prepared with distilled water and filtered with a 0.22 μm sterile filter. As the positive control, aliquots of 100 μL of 1× concentrated MHB and 100 μL containing 106 CFUs per mL were used, while for negative controls, aliquots of 200 μL of sterile MHB were used. The compounds sterility was also tested. The microtiter plates were then incubated at 37 °C for 20 h and bacterial growth was assessed by determining the optical density (OD) of cultures at 640 nm using a SPECTROstarNano (BMG LABTECH) microplate reader. Experiments were carried out at least four times.

4. Conclusions

In summary, our previous studies attested to the antibacterial properties of cyclam-based compounds. The results described herein allow for the establishment of the precise relations between the antibacterial activity and the structural features of the compounds derived from saturated tetraazamacrocycles. Specifically, it has been shown that: i) the number of pendant arms on the macrocyclic backbone; ii) the nature; iii) the relative positions of the substituents on the aromatic ring of the pendant arms; and iv) the size of the macrocycle cavity, are critical issues. The design of new macrocyclic molecules that systematically display variations of these properties, aiming to highlight and optimize their antimicrobial activity is a current topic of much interest to us.
The beneficial effect of the coordination of Fe2+ and Mn2+ to tetraazamacrocycles has been reported by Hubin et al. [14,16] and Khan et al. [15]. Our future research will investigate the antimicrobial activities of metal complexes supported by cyclam and cyclen ligands.

Supplementary Materials

The following are available online at https://www.mdpi.com/2079-6382/8/4/224/s1: NMR spectra (Figures S1–S19), Table S1: Hydrogen bond distances (Å) and angles (°) in compound 14, Table S2: Crystal data and structure refinement for compounds 8 and 14.

Author Contributions

L.G.A., J.F.P. and S.A. performed the synthesis and characterization of the compounds; J.F.P., S.A.S. and O.F. performed the bacterial growth inhibition experiments; L.G.A., E.R.S., A.M.M. and J.H.L. supervised the experiments and wrote the manuscript; L.G.A., S.A.S., A.M.M. and J.H.L. conceived the experiments.

Funding

This research was funded by Fundação para a Ciência e a Tecnologia, projects UI/QUI/0100/2019 and UID/BIO/04565/2019 and grants PD/BD/128370/2017, SFRH/BPD/88135/2012 and SFRH/BPD/86815/2012. Programa Operacional Regional de Lisboa 2020 (Project N.007317) is also acknowledged for funding iBB.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Walsh, C.T.; Wencewicz, T.A. Prospects for new antibiotics: A molecule-centered perspective. J. Antibiot. 2014, 67, 7–22. [Google Scholar] [CrossRef]
  2. Bartlett, J.G.; Gilbert, D.N.; Spellberg, B. Seven Ways to Preserve the Miracle of Antibiotics. Clin. Infect. Dis. 2013, 56, 1445–1450. [Google Scholar] [CrossRef]
  3. Theuretzbacher, U. Future antibiotics scenarios: Is the tide starting to turn? Int. J. Antimicrob. Agents 2009, 34, 15–20. [Google Scholar] [CrossRef]
  4. Ghosh, C.; Sarkar, P.; Issa, R.; Haldar, J. Alternatives to Conventional Antibiotics in the Era of Antimicrobial Resistance. Trends Microbiol. 2019, 27, 323–338. [Google Scholar] [CrossRef] [PubMed]
  5. Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48, 1–12. [Google Scholar] [CrossRef] [PubMed]
  6. Singh, S.B.; Young, K.; Silver, L.L. What is an “ideal” antibiotic? Discovery challenges and path forward. Biochem. Pharmacol. 2017, 133, 63–73. [Google Scholar] [CrossRef] [PubMed]
  7. Liang, X.; Sadler, P.J. Cyclam complexes and their applications in medicine. Chem. Soc. Rev. 2004, 33, 246–266. [Google Scholar] [CrossRef] [PubMed]
  8. Mewis, R.E.; Archibald, S.J. Biomedical applications of macrocyclic ligand complexes. Coord. Chem. Rev. 2010, 254, 1686–1712. [Google Scholar] [CrossRef]
  9. Hermann, P.; Kotek, J. Eight-membered and larger Heterocyclic Rings and their Fused Derivatives, Other Seven-membered Rings. Compr. Heterocycl. Chem. III 2008, 14, 613–666. [Google Scholar]
  10. Pandya, D.N.; Bhatt, N.; Yuan, H.; Day, C.S.; Ehrmann, B.M.; Wright, M.; Bierbach, U.; Wadas, T.J. Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chem. Sci. 2017, 8, 2309–2314. [Google Scholar] [CrossRef]
  11. Gerlach, L.O.; Skerlj, R.T.; Bridger, G.J.; Schwartz, T.W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 2001, 276, 14153–14160. [Google Scholar] [CrossRef] [PubMed]
  12. Sakyiamah, M.M.; Kobayakawa, T.; Fujino, M.; Konno, M.; Narumi, T.; Tanaka, T.; Nomura, W.; Yamamoto, N.; Murakami, T.; Tamamura, H. Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands. Bioorgan. Med. Chem. 2019, 27, 1130–1138. [Google Scholar] [CrossRef] [PubMed]
  13. Khan, M.O.F.; Levi, M.S.; Tekwani, B.L.; Khan, S.I.; Kimura, E.; Borne, R.F. Synthesis and Antimalarial Activities of Cyclen 4-Aminoquinoline Analogs. Antimicrob. Agents Chemother. 2009, 53, 1320–1324. [Google Scholar] [CrossRef] [PubMed]
  14. Hubin, T.J.; Amoyaw, P.N.A.; Roewe, K.D.; Simpson, N.C.; Maples, R.D.; Freeman, T.N.C.; Amy, N.C.; Le, J.G.; Archibald, S.J.; Khan, S.I.; et al. Synthesis and antimalarial activity of metal complexes of cross-bridged tetraazamacrocyclic ligands. Bioorgan. Med. Chem. 2014, 22, 3239–3244. [Google Scholar] [CrossRef]
  15. Khan, M.O.F.; Keiser, J.; Amoyaw, P.N.A.; Hossain, M.F.; Vargas, M.; Le, J.G.; Simpson, N.C.; Roewe, K.D.; Freeman, T.N.C.; Hasley, T.R.; et al. Discovery of Antischistosomal Drug Leads Based on Tetraazamacrocyclic Derivatives and Their Metal Complexes. Antimicrob. Agents Chemother. 2016, 60, 5331–5336. [Google Scholar] [CrossRef]
  16. Hubin, T.J.; Walker, A.N.; Davilla, D.J.; Freeman, T.N.C.; Epley, B.M.; Hasley, T.R.; Amoyaw, P.N.A.; Jain, S.; Archibald, S.J.; Prior, T.J.; et al. Tetraazamacrocyclic derivatives and their metal complexes as antileishmanial leads. Polyhedron 2019, 163, 42–53. [Google Scholar] [CrossRef]
  17. Pilon, A.; Lorenzo, J.; Rodriguez-Calado, S.; Adão, P.; Martins, A.M.; Valente, A.; Alves, L.G. New Cyclams and their Copper(II) and Iron(III) Complexes: Synthesis and Potential Application as Anticancer Agents. ChemMedChem 2019, 14, 770–778. [Google Scholar] [CrossRef]
  18. Wen, J.-H.; Li, C.-Y.; Geng, X.-Y.; Wang, Z.-L. A potent antitumor Zn2+ tetraazamacrocycle complex targeting DNA: the fluorescent recognition, interaction and apoptosis studies. Chem. Commun. 2011, 47, 11330–11332. [Google Scholar] [CrossRef]
  19. Yu, M.; Nagalingam, G.; Ellis, S.; Martinez, E.; Sintchenko, V.; Spain, M.; Rutledge, P.J.; Todd, M.H.; Triccas, J.A. Nontoxic Metal−Cyclam Complexes, a New Class of Compounds with Potency against Drug-Resistant Mycobacterium tuberculosis. J. Med. Chem. 2016, 59, 5917–5921. [Google Scholar] [CrossRef]
  20. Spain, M.; Wong, J.K.-H.; Nagalingam, G.; Batten, J.M.; Hortle, E.; Oehlers, S.H.; Jiang, X.F.; Murage, H.E.; Orford, J.T.; Crisologo, P.; et al. Antitubercular Bis-Substituted Cyclam Derivatives: Structure–Activity Relationships and in Vivo Studies. J. Med. Chem. 2018, 61, 3595–3608. [Google Scholar] [CrossRef]
  21. Alves, L.G.; Pinheiro, P.F.; Feliciano, J.R.; Dâmaso, D.P.; Leitão, J.H.; Martins, A.M. Synthesis, antimicrobial activity and toxicity to nematodes of cyclam derivatives. Int. J. Antimicrob. Agents 2017, 49, 646–649. [Google Scholar] [CrossRef] [PubMed]
  22. Boiocchi, M.; Fabbrizzi, L.; Licchelli, M.; Sacchi, D.; Vázquez, M.; Zampa, C. A two-channel molecular dosimeter for the optical detection of copper(II). Chem. Commun. 2003, 15, 1812–1813. [Google Scholar] [CrossRef] [PubMed]
  23. Royal, G.; Dahaoui-Gindrey, V.; Dahaoui, S.; Tabard, A.; Guilard, R.; Pullumbi, C.L. New synthesis of trans-disubstituted cyclam macrocycles—Elucidation of the disubstitution mechanism on the basis of X-ray data and molecular modeling. Eur. J. Org. Chem. 1998, 9, 1971–1975. [Google Scholar] [CrossRef]
  24. Alves, L.G.; Antunes, M.A.; Matos, I.; Munhá, R.F.; Duarte, M.T.; Fernandes, A.C.; Marques, M.M.; Martins, A.M. Reactivity of a new family of diamido-diamine cyclam-based zirconium complexes in ethylene polymerization. Inorg. Chim. Acta 2010, 363, 1823–1830. [Google Scholar] [CrossRef]
  25. Alves, L.G.; Duarte, M.T.; Martins, A.M. Structural features of neutral and cationic cyclams. J. Mol. Struct. 2015, 1098, 277–288. [Google Scholar] [CrossRef]
  26. Arunan, E.; Desiraju, G.R.; Klein, R.A.; Sadlej, J.; Schneider, S.; Alkorta, I.; Clary, D.C.; Crabtree, R.H.; Dannenberg, J.J.; Hobza, P.; et al. Definition of the hydrogen bond (IUPAC Recommendations 2011). Pure Appl. Chem. 2011, 83, 1637–1664. [Google Scholar] [CrossRef]
  27. Leitão, J.H.; Sousa, S.A.; Leite, S.A.; Carvalho, M.F.N.N. Silver Camphor Imine Complexes: Novel Antibacterial Compounds from Old Medicines. Antibiotics 2018, 7, 65. [Google Scholar] [CrossRef]
  28. Limban, C.; Chifiriuc, M.C. Antibacterial Activity of New Dibenzoxepinone Oximes with Fluorine and Trifluoromethyl Group Substituents. Int. J. Mol. Sci. 2011, 12, 6432–6444. [Google Scholar] [CrossRef]
  29. Barefield, E.K. A New Synthesis of 1,4,8,11-Tetraazacyclotetradecane (Cyclam) via the Nickel(II) Complex. Inorg. Chem. 1972, 11, 2273–2274. [Google Scholar] [CrossRef]
  30. Touzi, H.; Chevalier, Y.; Bessueille, F.; Ouada, H.B.; Jaffrezic-Renault, N. Detection of dyestuffs with an impedimetric sensor based on Cu2+-methyl-naphthyl cyclen complex functionalized gold electrodes. Sens. Actuators B Chem. 2018, 273, 1211–1221. [Google Scholar] [CrossRef]
  31. Saint; Version 7.03A; Bruker AXS Inc.: Madison, WI, USA, 2003.
  32. Sheldrick, G.M. SADABS, Program for Empirical Absorption Corrections; University of Göttingen: Göttingen, Germany, 1996. [Google Scholar]
  33. Altomare, A.; Burla, M.C.; Camalli, M.; Cascarano, G.L.; Giacovazzo, C.; Guagliardi, A.; Moliterni, A.G.G.; Polidori, G.; Spagna, R. SIR97: A new tool for crystal structure determination and refinement. J. Appl. Cryst. 1999, 32, 115–119. [Google Scholar] [CrossRef]
  34. Sheldrick, G.M. Crystal structure refinement with SHELXL. Acta Cryst. 2015, C71, 3–8. [Google Scholar]
  35. Farrugia, L.J. WinGX suite for small-molecule single-crystal crystallography. J. Appl. Cryst. 1999, 32, 837–838. [Google Scholar] [CrossRef]
  36. Macrae, C.F.; Bruno, I.J.; Chisholm, J.A.; Edgington, P.R.; McCabe, P.; Pidcock, E.; Rodriguez-Monge, L.; Taylor, R.; van de Streek, J.; Wood, P.A. Mercury CSD 2.0—New features for the visualization and investigation of crystal structures. J. Appl. Cryst. 2008, 41, 466–470. [Google Scholar] [CrossRef]
  37. Leitão, J.H.; Sousa, S.A.; Cunha, M.V.; Salgado, M.J.; Melo-Cristino, J.; Barreto, M.C.; Sá-Correia, I. Variation of the antimicrobial susceptibility profiles of Burkholderia cepacia complex clonal isolates obtained from chronically infected cystic fibrosis patients: A five-year survey in the major Portuguese treatment center. Eur. J. Clin. Microb. Inf. Dis. 2008, 27, 1101–1111. [Google Scholar] [CrossRef]
Antibiotics 08 00224 sch001 550
Scheme 1. Synthetic route for the preparation of [H4{H2(4-CF3PhCH2)Cyclam}]Cl4, 5.
Scheme 1. Synthetic route for the preparation of [H4{H2(4-CF3PhCH2)Cyclam}]Cl4, 5.
Antibiotics 08 00224 sch001
Antibiotics 08 00224 g001 550
Figure 1. Mercury diagram of 8. Selected hydrogen atoms are omitted for clarity. Half of the molecule is generated by the symmetry operation −x+1, −y, −z.
Figure 1. Mercury diagram of 8. Selected hydrogen atoms are omitted for clarity. Half of the molecule is generated by the symmetry operation −x+1, −y, −z.
Antibiotics 08 00224 g001
Antibiotics 08 00224 sch002 550
Scheme 2. Synthetic route for the preparation of compounds 6–21.
Scheme 2. Synthetic route for the preparation of compounds 6–21.
Antibiotics 08 00224 sch002
Antibiotics 08 00224 g002 550
Figure 2. Mercury diagram of 14b. Selected hydrogen atoms are omitted for clarity. Dashed lines represent hydrogen bonds. Half of the molecule is generated by the symmetry operations −x−2, −y+2, −z and −x−1, −y+2, −z+1.
Figure 2. Mercury diagram of 14b. Selected hydrogen atoms are omitted for clarity. Dashed lines represent hydrogen bonds. Half of the molecule is generated by the symmetry operations −x−2, −y+2, −z and −x−1, −y+2, −z+1.
Antibiotics 08 00224 g002
Antibiotics 08 00224 sch003 550
Scheme 3. Synthetic route for the preparation of [H4(H4Cyclam)]Cl4, 22.
Scheme 3. Synthetic route for the preparation of [H4(H4Cyclam)]Cl4, 22.
Antibiotics 08 00224 sch003
Antibiotics 08 00224 sch004 550
Scheme 4. Synthetic route for the preparation of [H4{H2(4-CF3PhCH2)2Cyclen}]Cl4, 25.
Scheme 4. Synthetic route for the preparation of [H4{H2(4-CF3PhCH2)2Cyclen}]Cl4, 25.
Antibiotics 08 00224 sch004
Table
Table 1. Minimal inhibitory concentration (MIC) (µg/mL) determined for Staphylococcus aureus Newman and Escherichia coli ATCC25922 in Mueller–Hinton broth (MHB) liquid media.
Table 1. Minimal inhibitory concentration (MIC) (µg/mL) determined for Staphylococcus aureus Newman and Escherichia coli ATCC25922 in Mueller–Hinton broth (MHB) liquid media.
CompoundS. aureus NewmanE. coli ATCC25922
Antibiotics 08 00224 i0015>512>512
Antibiotics 08 00224 i00211>512250.6 ± 7.6
Antibiotics 08 00224 i003127.0 ± 0.46.2 ± 1.0
Antibiotics 08 00224 i00413239.1 ± 24.074.6 ± 18.5
Antibiotics 08 00224 i0051414.2 ± 0.29.8 ± 0.5
Antibiotics 08 00224 i0061514.8 ± 0.28.0 ± 0.2
Antibiotics 08 00224 i00716>512201.3 ± 18.5
Antibiotics 08 00224 i008177.3 ± 0.24.3 ± 0.2
Antibiotics 08 00224 i00918119.5 ± 9.357.7 ± 8.3
Antibiotics 08 00224 i0101914.5 ± 0.510.0 ± 1.4
Antibiotics 08 00224 i0112015.0 ± 0.17.2 ± 0.1
Antibiotics 08 00224 i012219.0 ± 0.46.3 ± 1.7
Antibiotics 08 00224 i01322>512>512
Antibiotics 08 00224 i0142516.0 ± 0.28.7 ± 0.7
Data are presented as mean ± SEM. Values are the result of at least three independent experiments, each performed in triplicate.

Share and Cite

MDPI and ACS Style

Alves, L.G.; Portel, J.F.; Sousa, S.A.; Ferreira, O.; Almada, S.; Silva, E.R.; Martins, A.M.; Leitão, J.H. Investigations into the Structure/Antibacterial Activity Relationships of Cyclam and Cyclen Derivatives. Antibiotics 2019, 8, 224. https://doi.org/10.3390/antibiotics8040224

AMA Style

Alves LG, Portel JF, Sousa SA, Ferreira O, Almada S, Silva ER, Martins AM, Leitão JH. Investigations into the Structure/Antibacterial Activity Relationships of Cyclam and Cyclen Derivatives. Antibiotics. 2019; 8(4):224. https://doi.org/10.3390/antibiotics8040224

Chicago/Turabian Style

Alves, Luis G., João F. Portel, Sílvia A. Sousa, Olga Ferreira, Stephanie Almada, Elisabete R. Silva, Ana M. Martins, and Jorge H. Leitão. 2019. "Investigations into the Structure/Antibacterial Activity Relationships of Cyclam and Cyclen Derivatives" Antibiotics 8, no. 4: 224. https://doi.org/10.3390/antibiotics8040224

APA Style

Alves, L. G., Portel, J. F., Sousa, S. A., Ferreira, O., Almada, S., Silva, E. R., Martins, A. M., & Leitão, J. H. (2019). Investigations into the Structure/Antibacterial Activity Relationships of Cyclam and Cyclen Derivatives. Antibiotics, 8(4), 224. https://doi.org/10.3390/antibiotics8040224

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop